Acapela Group

Acapela Group

Acapela Group began developing text-to-speech technology before terms like AI and voice became mainstream, now operating from headquarters near Toulouse with offices in Belgium, Germany, and Sweden. The company's founding was driven by a vision to create natural, accessible voices using proprietary deep neural network technology, and it has held early-mover status in custom voice creation, children's voices, and rare-language support. The firm focuses on direct co-investments and SPVs in seed-stage startups across EdTech and assistive technology. Its deployment spans at least three asset classes: custom voice development, voice-preservation services for medical use, and licensing AI voice engines to enterprise clients. Confirmed partnerships include Team Gleason, Boston Children's Hospital, several US VA centers, and the Norwegian Labour and Welfare Administration (Nav). Geographic reach covers North America and Europe. Acapela Group's disclosed team size is not publicly specified, but the firm describes itself as human-scale. Its adjacent vehicles include a dedicated division, Acapela Inclusive, which specifically targets accessibility markets for speech impairments, learning disabilities, visual impairments, and seniors. February 2019: Team Gleason added Acapela's My-Own-Voice to its synthetic voice options for people living with ALS. A structural differentiator is Acapela Group's self-imposed ethical framework — prioritizing speaker consent, data protection, and minimal environmental resource use in AI voice creation. The firm also offers voice preservation via a secure USB solution, enabling individuals to protect their digital voice identity outside of cloud dependency.